Neuropeptides Peptides
Signaling peptides active in the nervous system that modulate neurotransmission, pain perception, and neuroendocrine function. Includes substance P analogs, neuropeptide Y, and related compounds.
Other Categories
Related Categories
Dihexa
Dihexa (PNB-0408): angiotensin IV-derived peptide that potentiates HGF/c-Met signaling. Covers preclinical cognitive enhancement research, oral bioavailability, and safety considerations.
Kisspeptin
Kisspeptin: Master HPG axis regulator for fertility research. Covers GnRH neuron activation, Phase 2 trial data, IVF applications, and safety.
Nemifitide
Nemifitide (INN-00835): pentapeptide MIF-1 analog with rapid-onset antidepressant effects (5-7 days). Phase 3 clinical trials for major depressive disorder.
Neuropeptide Y
Neuropeptide Y (NPY): 36-amino acid endogenous peptide regulating stress resilience, appetite, and anxiety. Intranasal delivery studied for depression and PTSD.
Oveporexton
Oveporexton (TAK-861): first-in-class oral OX2R-selective agonist for narcolepsy type 1. Phase 3 FirstLight/RadiantLight trial results, mechanism, dosing, and NDA filing status.
PE-22-28
PE-22-28: synthetic spadin analog TREK-1 potassium channel blocker. Preclinical antidepressant effects and hippocampal neurogenesis within 4 days of treatment.
Rapastinel
Rapastinel (GLYX-13): NMDA receptor glycine-site partial agonist. Covers phase 2 antidepressant results, failed phase 3 trials, and rapid-acting mechanism.
VIP
VIP: Vasoactive Intestinal Peptide guide. Covers vasodilation, gut motility, CIRS/mold illness research, circadian effects, and immune modulation.
Head-to-Head Comparisons
Detailed comparisons between neuropeptides peptides covering mechanisms, efficacy, side effects, and research evidence.
Related Articles
Dihexa (PNB-0408): Structure, Solubility, Paper Controversy & Research Status in 2026
Deep-dive into Dihexa (PNB-0408): chemical structure (C27H44N4O5, MW 504.66), solubility data, the retracted Benoist 2014 paper, HGF/c-Met controversy, and where research stands in 2026.
guidePeptide Therapy for Brain Health: Neuroprotection, Cognition, and Recovery
Comprehensive guide to peptides for brain health covering neurotrophic factors, neuroprotective agents, anxiolytics, and experimental cognitive enhancers. Includes cerebrolysin, semax, selank, BPC-157, dihexa, pinealon, SS-31, and rapastinel.
guideNootropic Peptide Stacks: What Research Says About Combining Cognitive Peptides
Evidence-based review of nootropic peptide stacking, including Semax+Selank combinations, BDNF upregulation stacks, and neuroprotective synergies.
research-reviewPeptides for Brain Injury and Neuroprotection: TBI, Stroke, and Neurodegeneration Research
Research review of neuroprotective peptides for TBI, stroke, and neurodegeneration, including Semax, Davunetide, BPC-157, and Dihexa.
guideBest Nootropic Peptides for Cognitive Enhancement: 2026 Guide
Comprehensive 2026 guide to 9 nootropic peptides for cognitive enhancement — dihexa, semax, selank, cerebrolysin, PE-22-28, davunetide, pinealon, humanin, and DSIP — grouped by mechanism including BDNF upregulation, synaptogenesis, neuroprotection, and anxiolytic/sleep pathways.
guideFDA Peptide Categories Explained: Category 1 vs Category 2 (2026)
Understand the FDA peptide classification system. Learn the difference between Category 1, Category 2, and Category 3 peptides and what the 2024-2026 regulatory changes mean for researchers.
Research Tools
Use our interactive tools to explore neuropeptides peptides further.